Skip to content
  • Research
  • Insights
  • Testimonials
  • Blog
  • White Papers
  • About
  • Contact Us
Menu
  • Research
  • Insights
  • Testimonials
  • Blog
  • White Papers
  • About
  • Contact Us

FDA Expands Transparency, Disclosure of KOL Involvement, Mirroring Pharma Trend

  • May 5, 2010

A recent Pharmaceutical Executive article outlined new US Food and Drug Administration draft guidance that would “expand transparency and disclosure when the agency grants a conflict of interest waiver to permit an individual’s participation at an FDA advisory committee meeting.”

The FDA, much like the many public and private companies that make up the biopharmaceutical industry, relies on the expertise and advice of research scientists and health care professionals as resources for policy-making that affects the public health of the United States.  The draft guidance seeks to implement new guidelines for identifying potential conflicts of interest among the scientists and physicians drafted to help form wide-ranging policy throughout the health care industry.

The FDA’s self-policing initiative mirrors the ongoing trend in the biopharmaceutical industry for greater ethics and transparency.  Pharmaceutical companies are embracing greater disclosure of their activities with thought leaders in the medical community, and they are turning to companies like Thought Leader Select for targeted advice on a variety of fronts where they engage thought leaders. Thought Leader Select’s advisory services span a variety of KOL development areas, including help with advisory boards, conferences, regulatory approval, clinical research, and many other aspects of the development of new medicines.

Thought Leader Select provides an unbiased, third-party perspective that proves vital to evolving pharmaceutical development needs through intensive documentation of the skills and experience of researchers and physicians.  In addition to company’s industry-leading research methodology, Thought Leader Select can develop engagement plans between companies and thought leaders to ensure compliance and transparency with all ethical policies.

Read the full Pharmaceutical Executive article here.

More Posts

Understanding Customer Beliefs and Preferences

By Paul Meade, Patient Engagement Lead  In 2022, there are hundreds of thousands of healthcare companies in the United States alone. With this level of

Metrics That Determine Success for Field Medical Teams

By Mark Schoeman, General Manager When you’re in the medical field, one of the key things you need to be thinking about is what your

Technology is Getting Smarter

By Paul Meade, Patient Engagement Lead  It has become apparent that in order for a healthcare organization to succeed, they need to be able to

Thought Leader Thursday: The Evolving KOL/MSL Engagement Model

Mark Schoeman, General Manager at Clear Point Health talks about the ways in which the KOL/MSL engagement model is changing.

Share:

Send Us A Message

  • Research
  • Insights
  • Testimonials
  • Blog
  • White Papers
  • About
  • Contact Us
Menu
  • Research
  • Insights
  • Testimonials
  • Blog
  • White Papers
  • About
  • Contact Us
logo-2020-300.png

1589 W. 5th Street
Washington, NC 27889
email

© 2021 All rights Reserved. THOUGHT LEADER SELECT

Facebook-f Twitter Linkedin